AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32163675 — intervention group
Group type: EXPERIMENTAL
Intervention: Median symptom-to-balloon time
Number of subjects: 158
Study 32164435 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion during exercise testing
Number of subjects: 13
Study 32164435 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion
Number of subjects: 13
Study 32164435 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise testing with isoproterenol
Number of subjects: 13
Study 32164542 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional home care model with a highly trained team designed for preventive home interventions.
Number of subjects: 0
Study 32164542 — intervention group
Group type: COMPARATOR
Intervention: Traditional integrated home care model.
Number of subjects: 0
Study 32164542 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional home care model with a highly trained team.
Number of subjects: 0
Study 32164567 — intervention group
Group type: EXPERIMENTAL
Intervention: ENDING-S
Number of subjects: 220
Study 32164567 — intervention group
Group type: EXPERIMENTAL
Intervention: SOFA
Number of subjects: 220
Study 32164580 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Frailty Scale (CFS) assessment
Number of subjects: 294
Study 32164580 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS
Number of subjects: 294
Study 32164626 — intervention group
Group type: EXPERIMENTAL
Intervention: High homologous recombination deficiency (HRD)
Number of subjects: 19
Study 32164626 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor mutation burden (TMB)
Number of subjects: 19
Study 32164626 — intervention group
Group type: EXPERIMENTAL
Intervention: High HRD score
Number of subjects: 19
Study 32164691 — intervention group
Group type: EXPERIMENTAL
Intervention: Feel4Diabetes-intervention
Number of subjects: 45
Study 32164690 — intervention group
Group type: EXPERIMENTAL
Intervention: Feel4Diabetes intervention
Number of subjects: 27
Study 32164690 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening questionnaires (FINDRISC) and blood glucose measurement
Number of subjects: 27
Study 32164690 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention intensity
Number of subjects: 27
Study 32164690 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants < 45 years
Number of subjects: 27
Study 32164690 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary review
Number of subjects: 27
Study 32164704 — intervention group
Group type: EXPERIMENTAL
Intervention: Free vitamin D
Number of subjects: 90
Study 32164704 — intervention group
Group type: COMPARATOR
Intervention: Total serum vitamin D
Number of subjects: 90
Study 32164707 — intervention group
Group type: EXPERIMENTAL
Intervention: Informative booklet about palliative care issues
Number of subjects: 38
Study 32164760 — intervention group
Group type: EXPERIMENTAL
Intervention: Haploidentical donor (HID) transplant
Number of subjects: 278
Study 32164760 — intervention group
Group type: COMPARATOR
Intervention: HLA-matched sibling donor (MSD) transplant
Number of subjects: 278
Study 32164884 — intervention group
Group type: EXPERIMENTAL
Intervention: POC-hs-cTnI-TriageTrue
Number of subjects: 1261
Study 32164884 — intervention group
Group type: COMPARATOR
Intervention: hs-cTnT-Elecsys
Number of subjects: 1261
Study 32164884 — intervention group
Group type: COMPARATOR
Intervention: hs-cTnI-Architect
Number of subjects: 1261
Study 32164884 — intervention group
Group type: EXPERIMENTAL
Intervention: 0/1-h algorithm
Number of subjects: 1261
Study 32164884 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruled-out patients
Number of subjects: 1261
Study 32164898 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32164981 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with cytotoxic chemotherapy (4 cycles)
Number of subjects: 72
Study 32165033 — intervention group
Group type: EXPERIMENTAL
Intervention: Rett Syndrome Behavioural Questionnaire
Number of subjects: 149
Study 32165065 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab
Number of subjects: 84
Study 32165065 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 84
Study 32165096 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX-based therapy
Number of subjects: 1532
Study 32165096 — intervention group
Group type: EXPERIMENTAL
Intervention: TIL density
Number of subjects: 1532
Study 32165096 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor budding
Number of subjects: 1532
Study 32165096 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined variable of TIL density and tumor budding
Number of subjects: 1532
Study 32165181 — intervention group
Group type: EXPERIMENTAL
Intervention: WiSE-CRT system
Number of subjects: 90
Study 32165240 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (>5% over 8 weeks)
Number of subjects: 117
Study 32166305 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral treatment for HCV
Number of subjects: 177
Study 32166491 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural network
Number of subjects: 0
Study 32166491 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest
Number of subjects: 0
Study 32166491 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression
Number of subjects: 0
Study 32166491 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-RADS classification
Number of subjects: 0
Study 32166491 — intervention group
Group type: EXPERIMENTAL
Intervention: Binary visual analysis
Number of subjects: 0
Study 32166621 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids prescribed at discharge
Number of subjects: 110
Study 32166621 — intervention group
Group type: EXPERIMENTAL
Intervention: Unused opioids at follow-up
Number of subjects: 110
Study 32166621 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage of opioids in the home
Number of subjects: 110
Study 32167657 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergame (Nintendo Wii)
Number of subjects: 605
Study 32167657 — intervention group
Group type: COMPARATOR
Intervention: Motivational support (control)
Number of subjects: 605
Study 32167803 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy interventions, specific details not available
Number of subjects: 0
Study 32167861 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemarituzumab (FPA144) at doses of 0.3 to 15 mg/kg every 2 weeks
Number of subjects: 79
Study 32167861 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemarituzumab (FPA144) at doses of ≥ 10 mg/kg every 2 weeks for ≥ 70 days
Number of subjects: 79
Study 32168157 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 10
Study 32168159 — intervention group
Group type: EXPERIMENTAL
Intervention: CONVENTIONAL
Number of subjects: 7
Study 32168159 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST
Number of subjects: 7
Study 32168224 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV antibody positive women (case group)
Number of subjects: 131
Study 32168224 — intervention group
Group type: COMPARATOR
Intervention: HCV antibody negative women (control group)
Number of subjects: 131
Study 32168240 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone-hydrogel daily disposable contact lenses (delefilcon A)
Number of subjects: 50
Study 32168240 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel daily disposable contact lenses (omafilcon A)
Number of subjects: 50
Study 32168240 — intervention group
Group type: EXPERIMENTAL
Intervention: Initially symptomatic subjects (OSDI ≥13)
Number of subjects: 50
Study 32168240 — intervention group
Group type: EXPERIMENTAL
Intervention: Initially asymptomatic subjects (OSDI <13)
Number of subjects: 50
Study 32168240 — intervention group
Group type: COMPARATOR
Intervention: Baseline vs. post-study visits for OSDI
Number of subjects: 50
Study 32168240 — intervention group
Group type: COMPARATOR
Intervention: Baseline vs. 12-month visit for OSDI
Number of subjects: 50
Study 32168240 — intervention group
Group type: COMPARATOR
Intervention: Baseline vs. 12-month visit for Contact Lens Dry Eye Questionnaire
Number of subjects: 50
Study 32168980 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept + FOLFIRI (fluorouracil, leucovorin, and irinotecan)
Number of subjects: 766
Study 32169050 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty assessment using Fried's frailty phenotype
Number of subjects: 93
Study 32169050 — intervention group
Group type: EXPERIMENTAL
Intervention: Baroreflex function assessment
Number of subjects: 93
Study 32169050 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthostatic decrements of BP to HUT-60°
Number of subjects: 93
Study 32169050 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported dizziness symptoms
Number of subjects: 93
Study 32169255 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative performance on the Trail Making Test
Number of subjects: 300
Study 32169255 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative performance on the Stroop test
Number of subjects: 300
Study 32169255 — intervention group
Group type: EXPERIMENTAL
Intervention: Colour-word matching Stroop test performance
Number of subjects: 300
Study 32169783 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (Du) 1500 mg every 3 weeks (q3w)
Number of subjects: 136
Study 32169783 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab (Tr) 75 mg q3w for 5 doses
Number of subjects: 136
Study 32169783 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Du and Tr with platinum-doublet chemotherapy
Number of subjects: 136
Study 32169783 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (pemetrexed, gemcitabine, etoposide, nab-paclitaxel with cisplatin or carboplatin)
Number of subjects: 136
Study 32169872 — intervention group
Group type: EXPERIMENTAL
Intervention: hu14.18K322A mAb treatment
Number of subjects: 38
Study 32169872 — intervention group
Group type: EXPERIMENTAL
Intervention: PATA+ status
Number of subjects: 38
Study 32169927 — intervention group
Group type: EXPERIMENTAL
Intervention: Symphysis-fundal height (SFH) measurement
Number of subjects: 1486
Study 32169927 — intervention group
Group type: EXPERIMENTAL
Intervention: SFH <26 cm for GA <28 weeks
Number of subjects: 1486
Study 32169927 — intervention group
Group type: EXPERIMENTAL
Intervention: SFH <29 cm for GA <34 weeks
Number of subjects: 1486
Study 32169927 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated uterine volume (EUV)
Number of subjects: 1486
Study 32169927 — intervention group
Group type: EXPERIMENTAL
Intervention: Best model without including last menstrual period
Number of subjects: 1486
Study 32169933 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer (AG)
Number of subjects: 88
Study 32169933 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit (FB)
Number of subjects: 88
Study 32169933 — intervention group
Group type: COMPARATOR
Intervention: Both devices (AG and FB)
Number of subjects: 88
Study 32169933 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported physical activity
Number of subjects: 88
Study 32169933 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 88
Study 32169933 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 88
Study 32169933 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish-language pictograms
Number of subjects: 88
Study 32170554 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib plus chemotherapy (pemetrexed plus carboplatin)
Number of subjects: 81
Study 32170554 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib alone
Number of subjects: 81
Study 32170905 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided revascularization
Number of subjects: 2217
Study 32171061 — intervention group
Group type: EXPERIMENTAL
Intervention: MOR202 monotherapy (0.01 mg/kg to 16 mg/kg)
Number of subjects: 91
Study 32171061 — intervention group
Group type: EXPERIMENTAL
Intervention: MOR202 with dexamethasone
Number of subjects: 91
Study 32171061 — intervention group
Group type: EXPERIMENTAL
Intervention: MOR202 with dexamethasone plus pomalidomide
Number of subjects: 91
Study 32171061 — intervention group
Group type: EXPERIMENTAL
Intervention: MOR202 with dexamethasone plus lenalidomide
Number of subjects: 91
Study 32171061 — intervention group
Group type: EXPERIMENTAL
Intervention: MOR202 (all groups)
Number of subjects: 91
Study 32171069 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (360 mg/m) in combination with chemotherapy
Number of subjects: 38
Study 32171069 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (240 mg/m) during dose escalation
Number of subjects: 38
Study 32171104 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 (80-120 mg/day on days 1-14) and oxaliplatin (130 mg/m2) followed by surgery
Number of subjects: 29
Study 32171104 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 and oxaliplatin followed by surgery
Number of subjects: 29
Study 32171470 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen-deprivation therapies (ADTs)
Number of subjects: 184
Study 32171470 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide (25μM)
Number of subjects: 184
Study 32171470 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrotestosterone (30nM)
Number of subjects: 184
Study 32171470 — intervention group
Group type: COMPARATOR
Intervention: Enzalutamide
Number of subjects: 184
Study 32171632 — intervention group
Group type: EXPERIMENTAL
Intervention: Down syndrome (trisomy 21)
Number of subjects: 0
Study 32171632 — intervention group
Group type: EXPERIMENTAL
Intervention: Velocardiofacial syndrome (del22q11)
Number of subjects: 0
Study 32172456 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use hydrophilic-coated (HC) catheters for 4 weeks
Number of subjects: 39
Study 32172456 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use hydrophilic-coated (HC) catheters
Number of subjects: 39
Study 32172456 — intervention group
Group type: COMPARATOR
Intervention: Reused catheters
Number of subjects: 39
Study 32172489 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 836826 (CD37 antibody) at doses ranging from 1 mg to 200 mg, with a maximum tolerated dose (MTD) of 100 mg; administered as an intravenous infusion once weekly for 4 weeks.
Number of subjects: 48
Study 32172643 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided second-generation group (n=95)
Number of subjects: 403
Study 32172643 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided third-generation group (n=308)
Number of subjects: 403
Study 32173192 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with iliac leg endoprosthesis without coverage of the hypogastric artery
Number of subjects: 364
Study 32173192 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of a hypogastric branched endograft
Number of subjects: 364
Study 32173192 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypogastric artery coverage with extension into the external iliac artery
Number of subjects: 364
Study 32173192 — intervention group
Group type: COMPARATOR
Intervention: Bilateral IAAs
Number of subjects: 364
Study 32173192 — intervention group
Group type: COMPARATOR
Intervention: No IAA
Number of subjects: 364
Study 32174828 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Number of subjects: 0
Study 32174828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32174840 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol administration
Number of subjects: 0
Study 32174840 — intervention group
Group type: COMPARATOR
Intervention: No asthma treatment
Number of subjects: 0
Study 32174840 — intervention group
Group type: COMPARATOR
Intervention: Asthmatic children without SCD
Number of subjects: 0
Study 32175519 — intervention group
Group type: EXPERIMENTAL
Intervention: small-quantity lipid-based nutrition supplement (LNS) containing >20 micronutrients
Number of subjects: 0
Study 32175519 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32175617 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor T-cell therapies (CAR T-cells)
Number of subjects: 0
Study 32175617 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose escalation trials
Number of subjects: 0
Study 32175968 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-minute informational video, placement of capnography monitors with a shortened warm-up period, laminated reminder cards, feedback during staff meetings
Number of subjects: 118
Study 32175968 — intervention group
Group type: COMPARATOR
Intervention: Existing policy for capnography use
Number of subjects: 118
Study 32175969 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of adverse drug events (ADEs) by clinical pharmacists through structured interviews and medication history collection.
Number of subjects: 8275
Study 32176787 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem (1 g mixed with 200 mL normal saline, infused intravenously over 3 hours at 8-hour intervals, concentration 5 mg/mL, rate of infusion 5.5 mg/min)
Number of subjects: 25
Study 32176787 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 25
Study 32178232 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol
Number of subjects: 0
Study 32178232 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32178626 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial function assessment using reactive hyperemia index at 4-24 hours after surgery
Number of subjects: 83
Study 32178626 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial function assessment using reactive hyperemia index at postoperative day 3-5
Number of subjects: 83
Study 32178626 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine/ADMA ratio assessment at 4-24 hours after surgery
Number of subjects: 83
Study 32178626 — intervention group
Group type: EXPERIMENTAL
Intervention: Major adverse cardiovascular events within 30 days of surgery
Number of subjects: 83
Study 32178676 — intervention group
Group type: COMPARATOR
Intervention: Polyacrylamide gel electrophoresis Lipoprint© System for lipoprotein profile analysis
Number of subjects: 19
Study 32179133 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report of symptoms in patients with mild to moderate cognitive impairment
Number of subjects: 1047
Study 32179133 — intervention group
Group type: COMPARATOR
Intervention: Self-report of symptoms in patients without cognitive impairment
Number of subjects: 1047
Study 32179633 — intervention group
Group type: EXPERIMENTAL
Intervention: Spartalizumab (1, 3, or 10 mg/kg Q2W; 3 or 5 mg/kg Q4W)
Number of subjects: 58
Study 32179633 — intervention group
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Number of subjects: 58
Study 32179935 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilisation during extracorporeal membrane oxygenation
Number of subjects: 0
Study 32179935 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32180164 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 5 µg
Number of subjects: 0
Study 32180164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32180754 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-UPCAT (Tele-monitored UPper Limb Children Action Observation Training)
Number of subjects: 29
Study 32181968 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial exposure
Number of subjects: 430
Study 32182156 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifirafenib (BGB-283)
Number of subjects: 0
Study 32182364 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional rituximab (4 weekly injections followed by 6 monthly injections)
Number of subjects: 20
Study 32182364 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional rituximab supplemented with autologous serum (for unresponsive cases)
Number of subjects: 20
Study 32182364 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional rituximab
Number of subjects: 20
Study 32182364 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional rituximab and serum retreatment
Number of subjects: 20
Study 32182364 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after treatment
Number of subjects: 20
Study 32182791 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus at 10 mg/day
Number of subjects: 25
Study 32182791 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus at 10 mg/day with octreotide LAR at 30 mg/month (18 patients)
Number of subjects: 25
Study 32182949 — intervention group
Group type: EXPERIMENTAL
Intervention: Curative intent radiotherapy with or without androgen deprivation therapy (ADT)
Number of subjects: 208
Study 32183229 — intervention group
Group type: EXPERIMENTAL
Intervention: Zebrafish avatar model for drug efficacy studies
Number of subjects: 24
Study 32183229 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy dose conversion formula
Number of subjects: 24
Study 32183762 — intervention group
Group type: EXPERIMENTAL
Intervention: Family cohesion
Number of subjects: 0
Study 32183762 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-caregiver communication
Number of subjects: 0
Study 32183803 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention aimed at increasing preparedness for caregiving and death, including videos and informative texts, and an online peer-support discussion forum.
Number of subjects: 0
Study 32183803 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 0
Study 32184035 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination Maintenance Score (VMS)
Number of subjects: 245
Study 32184035 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal quality of life score
Number of subjects: 245
Study 32184035 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of children in the household
Number of subjects: 245
Study 32184035 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiating breastfeeding at birth
Number of subjects: 245
Study 32184112 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR) program for 12 weeks
Number of subjects: 53
Study 32184302 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor environmental quality monitoring using sensors measuring air quality (carbon dioxide and coarse particles), temperature, relative humidity, light intensity, and noise levels at 1 min intervals.
Number of subjects: 10000
Study 32184302 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor environmental quality monitoring
Number of subjects: 10000